An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States

Inclusion Criteria

• •Men diagnosed with prostate cancer (≥1 claim for prostate cancer).
• •Treatment with apalutamide, darolutamide or enzalutamide initiated for the first time in the nmPC stage during the patient identification period.
• •Age ≥ 18 years at index date
• •At least 6 months of continuous eligibility in medical and pharmacy benefits prior to the index date
• •At least 6-months of continuous eligibility only in pharmacy benefits after the index date unless patient died before 6 months.